LuciOlap is an advanced targeted antineoplastic agent belonging to the poly (ADP-ribose) polymerase (PARP) inhibitor class, indicated for the treatment of hereditary or sporadic forms of ovarian, breast, pancreatic, and prostate cancers. The active pharmaceutical ingredient is olaparib at a strength of 150 mg supplied as film-coated tablets (Olaparib Film-coated Tablets 150 mg). The product is developed and manufactured by Lucius Pharmaceuticals.
Olaparib is a potent inhibitor of PARP enzymes (PARP1, PARP2, and PARP3). PARP enzymes play a critical role in DNA single-strand break repair. Inhibiting PARP in cells with homologous recombination deficiency (such as BRCA1 or BRCA2 mutations) leads to the accumulation of unrepaired DNA double-strand breaks, resulting in tumor cell death via the "synthetic lethality" mechanism. The drug is highly effective as maintenance and monotherapy.
Supplied in a package containing 120 tablets of 150 mg. Intended exclusively for oral administration under the strict supervision of an oncologist.
Key Clinical Features and Advantages of LuciOlap 150 mg:
- ✅ First-in-Class PARP Inhibitor: Selective blockade of DNA repair in BRCA-deficient tumors.
- ✅ Synthetic Lethality Principle: Selective destruction of cancer cells while sparing most healthy tissues.
- ✅ Broad Indications: Proven efficacy in ovarian, breast, pancreatic, and prostate cancers.
- ✅ Convenient Oral Dosing: Taken orally twice daily regardless of food intake.
- ✅ Lucius Pharmaceuticals Standards: High-quality, accessible generic alternative to the originator product (Lynparza).